316 related articles for article (PubMed ID: 31489524)
1. Chromatin-Remodeled State in Lymphoma.
Liu Y; Gonzalez Y; Amengual JE
Curr Hematol Malig Rep; 2019 Oct; 14(5):439-450. PubMed ID: 31489524
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of lymphomas in the era of epigenetics.
Chebly A; Chouery E; Ropio J; Kourie HR; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Blood Rev; 2021 Jul; 48():100782. PubMed ID: 33229141
[TBL] [Abstract][Full Text] [Related]
3. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
4. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic dysregulation in follicular lymphoma.
Araf S; Okosun J; Koniali L; Fitzgibbon J; Heward J
Epigenomics; 2016 Jan; 8(1):77-84. PubMed ID: 26698557
[TBL] [Abstract][Full Text] [Related]
6. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
7. The many layers of epigenetic dysfunction in B-cell lymphomas.
Jiang Y; Dominguez PM; Melnick AM
Curr Opin Hematol; 2016 Jul; 23(4):377-84. PubMed ID: 27055146
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation and chromatin modifiers in colorectal cancer.
Vymetalkova V; Vodicka P; Vodenkova S; Alonso S; Schneider-Stock R
Mol Aspects Med; 2019 Oct; 69():73-92. PubMed ID: 31028771
[TBL] [Abstract][Full Text] [Related]
10. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
11. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.
Yusufova N; Kloetgen A; Teater M; Osunsade A; Camarillo JM; Chin CR; Doane AS; Venters BJ; Portillo-Ledesma S; Conway J; Phillip JM; Elemento O; Scott DW; Béguelin W; Licht JD; Kelleher NL; Staudt LM; Skoultchi AI; Keogh MC; Apostolou E; Mason CE; Imielinski M; Schlick T; David Y; Tsirigos A; Allis CD; Soshnev AA; Cesarman E; Melnick AM
Nature; 2021 Jan; 589(7841):299-305. PubMed ID: 33299181
[TBL] [Abstract][Full Text] [Related]
12. Chromatin Remodeling and Epigenetic Regulation in Plant DNA Damage Repair.
Kim JH
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443358
[TBL] [Abstract][Full Text] [Related]
13. DOC1-Dependent Recruitment of NURD Reveals Antagonism with SWI/SNF during Epithelial-Mesenchymal Transition in Oral Cancer Cells.
Mohd-Sarip A; Teeuwssen M; Bot AG; De Herdt MJ; Willems SM; Baatenburg de Jong RJ; Looijenga LHJ; Zatreanu D; Bezstarosti K; van Riet J; Oole E; van Ijcken WFJ; van de Werken HJG; Demmers JA; Fodde R; Verrijzer CP
Cell Rep; 2017 Jul; 20(1):61-75. PubMed ID: 28683324
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.
Serganova I; Chakraborty S; Yamshon S; Isshiki Y; Bucktrout R; Melnick A; Béguelin W; Zappasodi R
Front Cell Dev Biol; 2021; 9():805195. PubMed ID: 35071240
[TBL] [Abstract][Full Text] [Related]
15. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers.
Alver BH; Kim KH; Lu P; Wang X; Manchester HE; Wang W; Haswell JR; Park PJ; Roberts CW
Nat Commun; 2017 Mar; 8():14648. PubMed ID: 28262751
[TBL] [Abstract][Full Text] [Related]
16. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
18. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylating Agents in Lymphoma.
Cogan JC; Liu Y; Amengual JE
Curr Treat Options Oncol; 2020 Jun; 21(8):61. PubMed ID: 32601883
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).
Isshiki Y; Melnick A
Curr Cancer Drug Targets; 2021; 21(4):274-282. PubMed ID: 33413063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
